AAVP Biosystems

AAVP Biosystems is a biotechnology company focused on the development of a novel class of targeted gene delivery vectors for cancer therapy. The company's proprietary platform, the Adeno-associated virus phage (AAVP), is a hybrid vector that integrates the tissue-targeting specificity of filamentous bacteriophages with the robust eukaryotic gene expression of adeno-associated viruses (AAV). This technology enables the systemic administration of gene therapies that selectively home to tumor-associated receptors, such as integrins, while minimizing off-target effects in healthy organs. AAVP Biosystems is primarily advancing its pipeline in the field of oncology, with a particular emphasis on treating glioblastoma and other hard-to-treat solid tumors.